Royal Bank Of Canada Aeglea Bio Therapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.11 - $0.46 $144 - $605	1,317 New	1,317 $0
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $276 - $588	727 Added 107.86%	1,401 $1,000
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $904 - $4,811	-1,809 Reduced 72.86%	674 $0
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $10,615 - $27,079	-5,677 Reduced 69.57%	2,483 $6,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $9,422 - $22,666	2,692 Added 49.23%	8,160 $39,000
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $15,087 - $19,890	2,502 Added 84.36%	5,468 $44,000
Q2 2021 Aug 16, 2021	BUY	$6.32 - $8.38 $18,745 - $24,855	2,966 New	2,966 $20,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.